Autologous
stem-cell transplantation (also known as autogeneic, autogenic, or
autogenous stem-cell transplantation or auto-SCT) is the autologous
transplantation of stem cells—which is, transplantation in which
the undifferentiated cells or stem cells (cells from which other
types of cells develop) are taken from a person, accumulated, and
given back to the same person later. Even though it is most often
executed by means of hematopoietic stem cells (antecedent of cells
that forms blood) in hematopoietic stem cell transplantation, in some
cases cardiac cells are used productively to fix the damages due to
heart attacks. Stem cell transplantation can be of two types -
Autologous stem-cell transplantation and allogenic stem cell
transplantation. In the later, the recipient and the donor of stem
cells are dissimilar people. In a good number of allogeneic
transplants, the stem cells are taken from a donor whose cell type
matches closely with the patient’s cell type. The best donor in
allogenic stem cell transplantation is an immediate family member,
generally a brother or sister. If the patient does not have a match
in his/her family, a donor may be found from the public. This is
often called a MUD or matched unrelated donor transplant. This type
of transplant (MUD) is generally riskier.
Request
for Sample PDF Copy:
https://www.coherentmarketinsights.com/insight/request-pdf/523
Increasing
prevalence of cancer will drive the overall autologous stem cell and
non-stem cell based therapies market
According
to a report by National Cancer Institute, in 2016, around 1,685,210
new cases of cancer were diagnosed in the U.S. alone. Moreover, it
was also noted that around 595,690 people died from the disease in
the same year. Autologous stem cell and non-stem cell based therapies
is likely to become one of the preferred treatment for cancer. As the
prevalence of cancer is rising at a considerable rate, the market is
likely to grow during the forecast period.
North
America, followed by Europe accounted for the major share of the
autologous stem cell and non-stem cell based therapies market. This
is due to minimization of risks related with the treatment. Moreover,
the demand for these treatments is high due to their ability to cure
a significant number of infectious diseases. Autologous stem cell and
non-stem cell based therapies do not need an outside donor; therefore
the treatment is less infectious and convenient. These factors are
likely to boost the growth of the market in North America.
Global
Top Players
Key
players in the global autologous stem cell and non-stem cell based
therapies market are investing heavily in their research and
development activities so as to gain an upper hand in the market.
Some of the major players operating in the market are NeoStem, Inc.,
Aastrom Biosciences, Fibrocell Science, Inc., Genzyme Corporation,
BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon
Corporation.
Autologous
stem cell and non-stem cell based therapies market Taxonomy
On
the basis of application, the global autologous stem cell and
non-stem cell based therapies market is classified into:
-
Neurodegenerative diseases
-
Cardiovascular diseases
-
Cancer and autoimmune diseases
-
Skin transplantation
-
Infectious disease
Find
the comprehensive research report here with a single click:
https://www.coherentmarketinsights.com/ongoing-insight/autologous-stem-cell-and-non-stem-cell-based-therapies-market-523
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment